Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for neoadjuvant treatment of resectable hepatocellular carcinoma with high risk of recurrence: A multicenter retrospective study

BACKGROUND: Early recurrence is common after surgical resection (SR) for hepatocellular carcinoma (HCC) with high risk of recurrence and is associated with poor prognosis. The combinations of lenvatinib (LEN), anti-PD-1 antibodies (PD-1) and transcatheter arterial chemoembolization (TACE) (triple th...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jun-Yi, Wu, Jia-Yi, Li, Yi-Nan, Qiu, Fu-Nan, Zhou, Song-Qiang, Yin, Zhen-Yu, Chen, Yu-Feng, Li, Bin, Zhou, Jian-Yin, Yan, Mao-Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534527/
https://www.ncbi.nlm.nih.gov/pubmed/36212494
http://dx.doi.org/10.3389/fonc.2022.985380

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534527/
https://www.ncbi.nlm.nih.gov/pubmed/36212494
http://dx.doi.org/10.3389/fonc.2022.985380

Ejemplares similares